NCT01539226已完成不适用
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,959
- 试验地点
- 12
- 主要终点
- HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm.
研究概览
简要总结
This is a double-blind, randomised, placebo-controlled study to assess the safety and efficacy of a silicone elastomer vaginal matrix ring.
详细描述
A multi center, randomized, double-blind, placebo=controlled safety and efficacy trial of a Dapivirine Vaginal Matrix Ring in healthy HIV-negative women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Women > 18 and < 45 years of age, at screening, who can provide informed consent;
- •Available for all visits and consent to follow all procedures scheduled for the trial;
- •Self-reported sexually active (defined as an average of at least one penetrative penile-vaginal coital act per month for the last 3 months prior to screening);
- •HIV-negative as determined by the HIV algorithm applied at screening and enrolment;
- •On a stable form of contraception as defined within section 5.4 and willing to continue on stable contraception for the duration of the clinical trial, unless post-menopausal or surgically sterilised;
- •Asymptomatic for genital infections at the time of enrolment (if a woman is diagnosed with any clinically significant curable STI, she must have initiated treatment at least 1 week prior to enrolment and have completed the full course of treatment);
- •Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures (e.g., by home visit or telephone; or via family or close neighbour contacts); confidentiality to be maintained;
- •Willing to refrain from participation in another research trial using drugs, vaccines, medical devices, microbicides or oral pre-exposure prophylaxis investigational drugs for the duration of the IPM 027 trial.
排除标准
- •Currently pregnant or last pregnancy within 3 months prior to screening or intends to become pregnant during trial participation;
- •Currently breast-feeding;
- •Non-therapeutic injection drug use in the 12 months prior to screening;
- •Participated in another research trial using drugs, medical devices, microbicides or oral pre-exposure prophylaxis agents within 60 days prior to screening;
- •Previously participated or currently participating in any HIV vaccine trial;
- •Untreated, clinically significant urogenital infections , e.g., urinary tract, or other sexually transmitted infections, or other gynaecological symptoms within 1 week prior to enrolment;
- •Has a Grade 2 or higher pelvic examination finding, according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events; Addendum 1 Female Genital Grading Table for Use in Microbicide Studies;
- •History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, diagnosed chronic and/or recurrent vulvovaginal candidiasis, urethral obstruction, incontinence or urge incontinence;
- •Any gynaecological surgery within 90 days prior to screening;
- •Any Grade 1 or higher baseline aspartate aminotransferase (AST), alanine transaminase (ALT), or platelet count, and any Grade 2 or higher baseline haematology, chemistry or urinalysis laboratory value according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events;
- •Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or a silicone elastomer;
- •Any history of diabetes mellitus and chronic use of oral corticosteroid therapy; and any uncontrolled serious chronic or progressive disease;
- •Cervical cytology at screening that requires cryotherapy, biopsy or treatment (other than for infection). Women with Grade 1 cervical cytology findings can be enrolled upon completion of the initial phase of evaluation if no current treatment is indicated (based on local standard of care for management of abnormal cervical cytology);
- •Any condition(s) that, in the opinion of the investigator, might put the participant at risk, or interfere with the trial objectives or the participant's adherence to trial requirements.
结局指标
主要结局
HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm.
时间窗: 24 months
HIV-1 seroconversion measured by rapid and specialised laboratory testing according to the comprehensive HIV testing algorithm.
All Adverse Events
时间窗: 24 months
Self-reports, physical examination, gynaecological assessments, including pelvic/speculum examination, laboratory tests and other indicated investigations. All AEs will be reported, regardless of grade or relatedness.
次要结局
- The Incidence Rate of HIV-2 Seroconversion.(24 months)
- The Incidence of Curable STIs(24 months)
- Percentage of Participants With Pregnancy in Each Trial Arm Over the IP Use Period;(24 months)
- The Percentage of Women Who Report Adherence to the Use of the Vaginal Ring Inserted Once Every 4 Weeks Over the Trial Period;(24 months)
- The Percentage of Women Who Report the Use of the Vaginal Ring as Acceptable;(24 months)
- The Percentage of Participants With HIV-1 Drug Resistance Mutations Among Participants Who Acquire HIV-1.(24 months)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
3 期
Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in WomenHIV InfectionsNCT01617096International Partnership for Microbicides, Inc.2,629
已完成
3 期
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin MonotherapyType 2 Diabetes Mellitus (T2DM)NCT04504396PegBio Co., Ltd.620
已完成
2 期
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe PruritusChronic Kidney DiseasesPruritusNCT03617536Cara Therapeutics, Inc.269
已完成
3 期
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)Central Abdominal BulgingNCT02398188Evofem Inc.793
已完成
3 期
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous FatCentral Abdominal BulgingNCT02397499Neothetics, Inc800